KEMRI-PHRD UG1 CASCADE NETWORK UNIT: CERVICAL CANCER PREVENTION FOR WOMEN LIVING WITH HIV RESEARCH - KEMRI-PHRD CLINICAL TRIAL SITE FOR CASCADE NETWORK ‘CERVICAL CANCER PREVENTION FOR WOMEN LIVING WITH HIV Project Summary/Abstract: Cervical cancer isthe leading cause of cancer-related deaths in women in eastern and southern Africa, the regions with the highest burden of HIV infection globally. An estimate of 88% of deaths caused by cervical cancer occur in low-resource setting (1). In East Africa, a quarter of new cervical cancer cases in 2020 could be attributed to HIV infection (2). Cervical cancer morbidity and mortality reflects s ubs tan ti a l in te rna ti ona l d iff er enc es with the highest risk populations carrying the greatest disease burden. The KEMRI-CCR-PHRD research clinic in partnership with LVCT Health Dhibiti HIV/TB PEPFAR/CDC program (supporting 31,800 PLHIV in central region of Kenya) have organized a consortium of HIV and cervical cancer clinical, research and program experts and through this application propose to join the UG1 as a Network clinical trial site and implement HIV/cervical cancer prevention studies. We propose to implement the UG1 Network studies at three selected HIV care clinics (Thika level 5, Ruiru level 4, Igegania level 4 hospitals) based in public hospitals in Kiambu county, a rural urban setting. These facilities are part of ten facilities implementing the ‘TIBA’ study (5R01CA258590-02 Mugo), an implementation science study evaluating the implementation of Screen and Treat (SAT) + Single Visit Approach (SVA) with Thermal Ablation (TA). We have capacity and resources to participate in all four proposed focal research areas; increase screening uptake, improve management of screen positives, facilitate precancer treatment access and optimize precancer treatments for cervical cancer prevention for WLWH. Through partnership with LVCT Health Dhibiti HIV/TB CDC/PEPFAR funded care program and leveraging on-going implementation science studies conducted in the selected public health facilities, we propose in Aim 1, to provide infrastructure to recruit, enroll and retain WLWH to the UG2 network studies. The three selected facilities have an estimate of 4,000 WLWH enrolled in the HIV/TB care clinics, with the option to expand to 10,000 by incorporating the ten TIBA study clinics. In Aim 2, we propose to interface with the UG1 Research Bases and U24 Network Coordinating Center during concept and protocol development to provide insights and input on issues pertaining to clinical significance, study feasibility, implementation and contribute towards raising up relevant priority research questions. KEMRI-CCR-PHRD co-PIs have participated in multiple multisite clinical trials and have been protocol chairs on network studies. In Aim 3, we propose to provide on-site operational leadership for the successful conduct of the network clinical trials. The KEMRI-CCR-PHRD research unit has 16 years’ experience conducting clinical research and has well tested standardized systems and materials for implementation of research in accordance with international regulatory requirements. This grant is part of the NCI-supported CASCADE Network, which focuses on scientifically justified, accountable U.S.–international clinical trials to generate rigorous evidence that improves HIV-associated cancer prevention, screening, and clinical care. By evaluating interventions across relevant populations and care settings, the CASCADE Network is designed to produce findings that are translatable to U.S. patients, including populations disproportionately affected by HIV and cancer, while also benefiting global populations.